A Randomized Trial to Assess Effects on Plasminogen Activator Inhibitor-1
暂无分享,去创建一个
W. Cushman | M. Pahor | W. Applegate | G. Somes | K. Johnson | R. Tracy | R. Shorr | K. Kottke-Marchant | S. Deitcher | L. Franse
[1] Kukin Ml. The Heart Outcomes Prevention Evaluation Study. , 2001, Current cardiology reports.
[2] H. Parving,et al. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. , 2001, Diabetes care.
[3] J. Williamson,et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials , 2000, The Lancet.
[4] S. Yusuf,et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .
[5] M. Shirotani,et al. Differential effects of enalapril and nitrendipine on the fibrinolytic system in essential hypertension. , 1999, American heart journal.
[6] M. Pahor,et al. Outcome Results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in Patients With Hypertension and NIDDM , 1998, Diabetes Care.
[7] T. Makris,et al. Haemostasis balance disorders in patients with essential hypertension. , 1997, Thrombosis research.
[8] A. Folsom,et al. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. , 1997, Circulation.
[9] M. Pfeffer,et al. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. , 1997, Circulation.
[10] C. Held,et al. Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol. Results from the Angina Prognosis study in Stockholm. , 1997, Circulation.
[11] M. Gascon,et al. The Coagulation and Fibrinolytic Responses of Baboons after In Vivo Thrombin Generation – Effect of Interleukin 6 , 1997, Thrombosis and Haemostasis.
[12] K. Kaikita,et al. Effects of imidapril therapy on endogenous fibrinolysis in patients with recent myocardial infarction , 1997, Clinical cardiology.
[13] P. Ridker,et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.
[14] R. Tracy,et al. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. , 1997, Clinical chemistry.
[15] H. Asakura,et al. Hypercoagulability and high lipoprotein(a) levels in patients with type II diabetes mellitus. , 1996, Atherosclerosis.
[16] J. Guralnik,et al. Long‐Term Survival and Use of Antihypertensive Medications in Older Persons , 1995, Journal of the American Geriatrics Society.
[17] B. Psaty,et al. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. , 1995, Circulation.
[18] R. Tracy,et al. The measurement of fibrinogen in population-based research. Studies on instrumentation and methodology. , 1994, Archives of pathology & laboratory medicine.
[19] A. Maseri,et al. Angiotensin II Increases Plasminogen Activator Inhibitor Type 1 and Tissue‐Type Plasminogen Activator Messenger RNA in Cultured Rat Aortic Smooth Muscle Cells , 1994, Circulation.
[20] J. Manson,et al. Prospective study of endogenous tissue plasminogen activator and risk of stroke , 1994, The Lancet.
[21] P. Ridker,et al. Endogenous tissue-type plasminogen activator and risk of myocardial infarction , 1993, The Lancet.
[22] W. Pettinger,et al. Single-drug therapy for hypertension in men. , 1993, The New England journal of medicine.